Fundraising Fox
Stockholm · Seed–Growth · 33 people tracked
Also known as HEALTHCAP ADVISOR AB · HEALTHCAP IX ADVISOR AB · HEALTHCAP VII ADVISOR AB · HEALTHCAP VIII ADVISOR AB
Find your way into HealthCap
Sign up to see every warm intro you have to HealthCap
- Paths you didn't know you had: your email and LinkedIn already hold routes to the HealthCap team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
HealthCap invests in and helps build life science companies developing breakthrough therapies with a high unmet medical need. It focuses on emerging therapeutics, particularly targeted treatments for rare diseases, cancers, and genetic diseases. The firm emphasizes deep medical expertise across medicine, finance, and biochemistry, and aims to challenge existing medical paradigms to find new ways to treat or cure diseases and improve quality of life. HealthCap stresses a responsible and sustainable approach to investing and ownership, collaborating with investors, academia, portfolio companies, patients, and other societal stakeholders to create long-term value and positive impact.
Source: firm website, verified Sep 29, 2026.
Team · 33 people
from the firm's website & curated & public directories
Founder mafia
3 people who came through HealthCap went on to found or lead other companies.
What they invest in
from 46 of 126 portfolio companiesBiotech ×40Healthtech ×30Medical Devices ×24Digital Health ×9Deep Tech ×5Hardware ×2AgTech ×1AI & Machine Learning ×1
HQs:United States×15Sweden×12Switzerland×2Germany×1Denmark×1Finland×1
Who they back
founder profiles across 18 portfolio companiesFounding team size:solo founder×102 founders×43 founders×24+ founders×2
What their founders studiedfrom 16 founders with field-of-study data
Life Sciences ×10Medicine ×3
Where their founders worked beforefrom 17 founders with career history
Göteborgs universitet ×2Linköping University ×2
Investments · 126 tracked
founders shown can be your intro pathBy year:2026 · 32025 · 22023 · 12022 · 22021 · 22020 · 42019 · 22018 · 32017 · 12015 · 32014 · 32012 · 130 dated
Pulmonx develops the Zephyr Valve, a bronchoscopic device used to treat patients with severe COPD/emphysema without surgery.
BiotechHealthtechMedical DevicesSan Jose, US
LAUREN CRISTINA(Executive Officer)inSri Radhakrishnan(Chief Technology Officer)inMICHAEL BAKER(Executive Officer, Director)inGlendon E. French(Chief Executive Officer and Director)Derrick Sung(Chief Operating Officer and Chief Financial Officer)inGeoffrey Beran Rose(Chief Commercial Officer)
Board seatStaffan Lindstrand· per SEC Form D
Co-investorsBand of AngelsKaiser Permanente VenturesKleiner PerkinsLatterell Venture PartnersMontreux Equity PartnersAlly Bridge Group
Spruce Biosciences develops and commercializes therapies for serious neurological and endocrine disorders with unmet medical need, with a lead investigational enzyme replacement therapy (TA-ERT) for Mucopolysaccharidosis Type IIIB (Sanfilippo Syndrome Type B).
BiotechHealthtechSouth San Francisco, US
Samir Gharib(Executive Officer)inRICHARD KING(Executive Officer, Director)inJavier Szwarcberg(Chief Executive Officer)in
BoardSimpson Camilla(Director)Tiba Aynechi(Director)inBali Muralidhar(Director)in
Board seatJonas Hansson· per SEC Form D
Co-investorsAisling CapitalRiverVest Venture PartnersAbingworthNorwest Venture PartnersNovo HoldingsOmega Funds+1 more
Hemab develops targeted therapies for bleeding and clotting disorders such as Glanzmann thrombasthenia, Factor VII deficiency, Von Willebrand Disease, and heavy menstrual bleeding.
BiotechDigital HealthHealthtechMedical Devices
Co-investorsAccess BiotechnologyAvoro Capital AdvisorsNovo HoldingsSofinnova PartnersRA Capital
Doctrin provides a communication platform that helps healthcare providers digitize the patient journey, including structured medical history intake and case triage to the right clinical professional.
Digital HealthEnterprise SoftwareHealthtechSaaSStockholm, SE
Co-investorsNorrsken VCNorrsken Accelerator
Gesynta Pharma is a pharmaceutical company developing non-hormonal, anti-inflammatory drug candidates that inhibit the mPGES-1 enzyme, with a lead program in endometriosis.
BiotechDigital HealthFemTechMedical DevicesStockholm, SE
Patric Stenberg(Founder)Gunilla Ekström(Founder)in
Co-investorsAmboy Street VenturesForeground CapitalHadean VenturesIndustrifondenXGEN VentureCatalyze Capital
Oncorena is a Swedish pharmaceutical company developing a breakthrough treatment for metastatic renal cancer based on the drug candidate ONC175 (orellanine).
BiotechHealthtechMedical DevicesStockholm, SE
Börje Haraldsson(Research lead)inJenny NyströminUlf NilssonLisa BuvallinPål FalckinSusanna Dahlgren(Chief Operating Officer)in
Co-investorsFSGGU Ventures AB
Priothera is a clinical-stage biotech developing mocravimod (an S1P receptor modulator) for hematologic malignancies such as acute myeloid leukemia.
BiotechHealthtech
Florent Gros(Chief Executive Officer and Founder)Stephan Oehen(Chief Operating Officer and Founder)inBrice Suire(Chief Financial Officer and Founder)Nigel Clark(Chief Business Officer)Jens Hasskarl(Chief Medical Officer)
Co-investorsFountain Healthcare Partners4see Ventures
SynOx Therapeutics develops emactuzumab, a monoclonal antibody treatment for tenosynovial giant cell tumours (TGCT) and macrophage-mediated diseases.
BiotechHealthtechMedical Devices
Ray Barlow(Chief Executive Officer)in
Co-investorsBioqube VenturesForbionGimvMedicxiRed Tree Venture
Tribune Therapeutics is a preclinical biopharmaceutical company developing medicines that target CCN protein family signaling (such as CCN2/CTGF) to block fibrotic pathways.
BiotechHealthtech
Ole Kaasbøll(Co-founder)
Co-investorsIndustrifondenInnovestor VenturesLifeArc VenturesInvestinorNovo Holdings
Vivet Therapeutics is a clinical-stage biotechnology company developing recombinant adeno-associated virus (rAAV) gene therapies for rare, inherited metabolic diseases, including Wilson's Disease and cerebrotendinous xanthomatosis.
BiotechHealthtechParis, FR
Co-investorsKurma PartnersNovartis Venture FundRoche Venture FundYsios CapitalColumbus Venture PartnersEurazeo+1 more
Incardatherapeutics develops drug therapies for treating atrial fibrillation using synergistic combinations of anti-arrhythmic agents, with delivery platforms designed for both hospital and at-home settings.
BiotechDigital HealthMedical DevicesBrisbane, US
Carlos A. Schuler(Executive Officer, Director)inJohn S. Patton(Executive Officer, Director)inRangachari Narasimhan(Executive Officer, Director)Grace Colon(Executive Officer, Director)inMiller Samantha(Executive Officer)
BoardMcCarthy Reenie(Director)
Board seatJohan Christenson· per SEC Form D
Co-investorsAsset Management CompanySofinnova VenturesDeerfield Management Company
BiotechRaleigh, US
Jaikrishna Patel(Executive Officer)Pierre Legault(Executive Officer, Director)inJames Mitchum(Director)John Hamill(Executive Officer)in
BoardRobert Seltzer(Director)
Board seatEugen Steiner· per SEC Form D · $28.5M raise · filed Nov 2015
Adcendo develops antibody-drug conjugates (ADCs) engineered to treat cancers with high unmet medical needs.
BiotechDigital HealthMedical Devices
Co-investorsVida VenturesYsios CapitalJeito Capital
Adcendo develops antibody-drug conjugates (ADCs) targeting cancers with high unmet medical need.
BiotechMedical Devices
Co-investorsVida VenturesJeito CapitalNovo HoldingsOrbiMedPontifax Venture CapitalRA Capital+3 more
Affibody is a biotechnology company developing radiopharmaceuticals and radioligand therapeutics based on its proprietary Affibody platform, aimed at treating cancer patients.
BiotechHealthtech
Algeta was a Norwegian oncology company developing alpha-particle radiopharmaceuticals, notably Xofigo (radium-223 dichloride) for bone metastases in prostate cancer.
Co-investorsAdvent Life SciencesBirk VentureAbingworth
AMRA Medical is a global health informatics company specializing in MRI-based fat distribution and muscle composition analysis for precision medicine applications.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesLinköping, SE
Magnus Borga(Co-Founder)inOlof Dahlqvist Leinhard(Chief Executive Officer, Co-Founder)in
Co-investorsIndustrifondenPfizer Venture Investments
RxList is an online medical resource providing detailed pharmaceutical information on brand and generic drugs, written and reviewed by pharmacists and physicians.
Digital HealthHealthtechMedia & EntertainmentSan Clemente, US
Co-investorsACVC PartnersAlleyCorpAnzu PartnersConstellation Technology VenturesIn-Q-TelMaverick Silicon+4 more
Aprea Therapeutics is a biopharmaceutical company developing novel cancer therapies targeting DNA damage response pathways to treat solid tumors including ovarian, colorectal, prostate, and breast cancers.
BiotechDigital HealthMedical DevicesDoylestown, US
John P. Hamill(Executive Officer)inOren Gilad(Chief Executive Officer, President)in
BoardJean-Pierre Bizzari(Director)Gabriela Gruia(Director)Rifat Pamukcu(Director)Bernd Seizinger(Director)
Co-investors5AM VenturesRobin Hood VenturesRosetta Capital Ltd.Versant VenturesSoleus Capital
Aro Biotherapeutics develops tissue-targeted genetic medicines using a proprietary protein technology called Centyrins.
BiotechHealthtechPhiladelphia, US
Karyn O'Neil(Executive Officer, Director)Susan Dillon(Founder)inMark V. Laurenzi(Executive Officer)
BoardElizabeth Anderson(Director)Bruce Peacock(Director)
Co-investorsAvego BioScience CapitalAgent CapitalBiotechnology Value FundCowen Healthcare InvestmentsJohnson & Johnson Innovation – JJDCNorthpond Ventures
BiotechSan Leandro, US
Steve Abella(Chief Medical Officer)inGraeme Currie(Chief Operating Officer)inStephen W. Lau(President, Chief Executive Officer, and Treasurer)inKenneth Schwartz(Executive Officer)inEric Yuen(Executive Officer)inMarten Steen(Director)in
Co-investorsEQT Life SciencesInkefSectoral Asset ManagementSofinnova VenturesYsios Capital
BoneSupport develops synthetic bone graft substitutes that remodel to match patient bone and elute antibiotics to prevent infection during healing.
BiotechHealthtechMedical Devices
Co-investorsIndustrifonden
CAR-Macrophage cellular therapeutics with initial oncology focus (NASDAQ: CARM).
BiotechPhiladelphia, US
Steven Kelly(Executive Officer, Director)in
BoardMargarita Chavez(Director)inEran Nadav(Director)Althea Stillman(Director)Jacob Gunterberg(Director)Regina Hodits(Director)in
Co-investorsAgent CapitalAju IB InvestmentAnzu PartnersGrazia Equity GmbHMRL Ventures FundSolasta Ventures+3 more
Carmeda develops the CARMEDA BioActive Surface, a heparin-based coating technology that it licenses to medical device manufacturers worldwide for use on their approved products.
BiotechMedical DevicesNew Materials
BiotechRadnor, US
Ruth Thieroff-Ekerdt(Executive Officer)Robert Lutz(Executive Officer)Alexander Lindstrom(Executive Officer)Matthew Pauls(Executive Officer)
BoardEigil Stray Spetalen(Director)Espen Tidemann Jorgensen(Director)
Co-investorsBirk Venture
CurifyLabs develops an automated compounding system for pharmacies that uses robotics, GMP-manufactured excipient bases, and integrated quality control software to enable faster, safer preparation of customized medications.
Digital HealthHealthtechMedical DevicesHelsinki, FI
Charlotta Topelius(CEO & Founder)inNiklas Sandler TopeliusNiklas Sandler(CTO & Founder)in
Co-investorsLifeline VenturesSandwaterTesi (Finnish Industry Investment Ltd)
Cytos is an orthobiologics company that develops biologic treatments for orthopedic conditions.
BiotechHealthtechMedical Devices
Co-investorsAisling Capital
Dynavax is a commercial-stage biopharmaceutical company that develops and commercializes vaccines against infectious diseases using its adjuvant technology.
BiotechHealthtechDüsseldorf, DE
Ryan Spencer(Chief Executive Officer)inDavid Novack(President and Chief Operating Officer)inRobert Janssen(Chief Medical Officer and Senior Vice President, Clinical Development)inKelly MacDonald(Chief Financial Officer)inJeff Coon(Chief Human Resources Officer)Donn Casale(Chief Commercial Officer)in
Co-investorsBain Capital Life SciencesSanderling Ventures
Biopharma developing HDL-C regulating therapies; listed 2000.
BiotechAnn Arbor, US
Roger S. Newton(Director)inTim M. Mayleben(Executive Officer, Director)
BoardDaniel Janney(Director)Dov A. Goldstein(Director)Nicole Vitullo(Director)inPatrick Enright(Director)in
Co-investorsAisling CapitalAlta PartnersArboretum VenturesARCHIMED JapanAsset Management CompanyCanaan Partners+3 more
Developed a next-generation iron chelator for iron overload in transfusion-dependent anemia; acquired by Shire in 2012.
BiotechSan Carlos, US
Hugh Y. Rienhoff, Jr., M.D.(Executive Officer, Director)in
BoardMarten Steen(Director)inDennis Henner, Ph.D.(Director)Bryant E. Fong(Director)
Co-investorsMC Healthcare VenturesClarus Ventures
Fusion Pharma develops targeted alpha therapeutics that link alpha-emitting medical isotopes to molecules targeting biomarkers on cancer cell surfaces to selectively kill tumor cells.
BiotechHealthtech
John Valliant(Founder)in
Co-investorsFACIT (Fight Against Cancer Innovation Trust)Lumira VenturesPivotal Life SciencesSeroba Life SciencesVenture OntarioYsios Capital+6 more
Kivu Bioscience develops antibody-drug conjugate (ADC) therapeutics in clinical development, advancing a pipeline of cancer treatments through strategic partnerships and collaborations.
BiotechDeep TechHealthtechMedical Devices
Mohit Trikha(CEO)inSophia Randolph(Chief Medical Officer)in
Co-investorsBioGeneration VenturesBOMGimvM VenturesRed Tree VentureNovo Holdings
Mahzi develops therapies for patients with under-diagnosed and under-served rare genetic neurodevelopmental disorders, working with patient and family groups, academic researchers, and industry partners.
BiotechHealthtechSouth San Francisco, US
Yael Weiss(Founder)in
BoardCamille Samuels(Director)inMarten Steen(Director)inShalini Sharp(Director)inStephen Farr(Director)
Co-investorsDroia VenturesHBM Healthcare InvestmentsHBM PartnersMitsui Global InvestmentVenrock
Modus is a Swedish biotechnology company developing sevuparin, a proprietary polysaccharide, as a treatment for conditions with high unmet medical need including sepsis and septic shock, severe systemic inflammation such as severe malaria, and anemia related to chronic inflammation like kidney disease.
Biotech
Neobiomics develops multi-strain food supplements rooted in academic research, with collaborations across Europe.
BiotechFoodTechHealthtechMedical DevicesWellness & FitnessStockholm, SE
Philipp Novak(Co-founder)inStefan Johansson(MD PhD, CMO)in
Norwegian clinical-stage biotech developing radiopharmaceuticals for hematological cancers; listed 2015.
Co-investorsBirk Venture
Oncopeptides develops therapeutics for cancer treatment.
BiotechHealthtechMedical Devices
Co-investorsIndustrifonden
OraPharma develops pharmaceutical products and tools for dental professionals to address oral health concerns, serving dental practices and patients.
HealthtechMedical DevicesBridgewater, US
Co-investorsA-Rod CorpCanaan PartnersFrazier Life SciencesOak Investment PartnersDomain Associates
OxThera develops a live biotherapeutic product based on oxalate-degrading bacteria to treat primary hyperoxaluria and other rare kidney diseases.
BiotechHealthtechMedical DevicesStockholm, SE
Elisabeth Lindner(Chief Operating Officer)Mats-Olof Wallin(Chief Financial Officer)Milt Allison
Co-investorsSunstone CapitalYsios Capital
Positrigo develops functional imaging technology to make diagnostic and clinical imaging scalable and accessible globally.
Deep TechHardwareHealthtechMedical Devices
Jannis Fischer(Founder)in
Co-investorskineo finance
Co-investorsBioMedPartnersInkefPontifax Venture CapitalV-Bio VenturesForbion
Pretzel Therapeutics develops therapeutics targeting bioenergetic dysfunction and mitochondrial disease by addressing defects in mitochondrial DNA function and gene expression.
BiotechDeep TechHealthtechMedical Devices
Michal Minczuk(Co-Founder)inGabriel Martinez(Chief Scientific Officer & Co-Founder)Claes Gustafsson(Co-Founder)Maria Falkenberg(Co-Founder)Nils-Göran Larsson(Co-Founder)Gabriel Martinez, Ph.D.(Chief Scientific Officer & Co-Founder)
Co-investorsARCH Venture PartnersCambridge Innovation CapitalEIR VenturesAngelini VenturesGV (Google Ventures)Invus+2 more
Developing safe, long-lasting gene therapy treatments in a redosable, non-viral format.
Louis Breton(Founder)in
This page is a news post from Azafaros, a biopharmaceutical company developing disease-modifying therapeutics for lysosomal storage disorders with a focus on neurological symptoms.
Biotech
Co-investorsCDP Venture CapitalIreland Strategic Investment FundAdams Street PartnersGenesys CapitalOrbiMedPivotal Life Sciences+1 more
Circio is a biotech company developing circular RNA technology (circVec) to improve AAV gene therapy expression for the treatment of genetic diseases.
BiotechDeep TechHealthtech
Co-investorsBirk Venture
Vicore Pharma is a clinical-stage biopharmaceutical company developing disease-modifying treatments for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis.
BiotechHealthtechMedical Devices
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Actelion Holding LtdAerocrine ABAlba Therapeutics CorpAltimmune, Inc. (Immune Targeting Systems Ltd)Apoxis SAAriceumAriceum TherapeuticsArpida AGAstaCarotene ABBioCrine ABBioFactor Therapeutics ABBiolipox ABBionaut Pharmaceuticals Inc.Biotage AB (Pyrosequencing AB)BrainCool AB (BeneChill Inc.)Cebix AB (Creative Peptides AB)CePep ABCerenis Therapeutics Holding S.AChemoCentryx Inc.Clinical Data Care in Lund ABClinitrac ABConpharm ABCoreValve SAElsa Science ABEsyTech ABFive Prime TherapeuticsGenizon BioSciences Inc. (Global Genomics)Glionova ABGyros ABHelloBetterHowtogetridofwartshomeIDEA AGInion OyJerini AGKaro Pharma (Karo Bio)Lica Pharmaceuticals A/SLTB4 Sweden ABLumavita AGMaxim Pharmaceuticals, Inc.Medicarb ABMelacure Therapeutics ABMillicore ABMIPS ABNeoventa Medical ABNephroGenex (BioStratum, Inc.)Neuro3D SANewron Pharmaceuticals SpA (NeuroNova AB)Nexstim OyNobex Corp.Nordic Vision Clinics AS (Optivy AB)NucleonicsOdyssey Thera Inc.Orchid BioSciences Inc.Orexo ABPersonal Chemistry ABPharmexa A/SPharmion Corp.ProCorde AGProlifix Ltd.Prothelia Inc.PTC Therapeutics Inc.Q-Med ABRainier Therapeutics Inc.Renovis Inc.Renovo Ltd.Resistentia Pharmaceuticals ABReVENT Medical Inc. (ReVent Medical International B.V.)RSPR Pharma ABSequenom Inc. (Eurona AB / Gemini Genomics plc)Sopherion Therapeutics Inc.Technolas Perfect Vision GmbHTengion IncTisbury PharmaceuticalTrigen Ltd.Trimb Healthcare ABTripep ABUltragenyx PharmaceuticalWilson Therapeutics
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 7
3 IPOs · 4 acquisitionsPulmonx Corp.NASDAQ: LUNGSpruce BiosciencesNASDAQ: SPRBHemab TherapeuticsNASDAQ: COAGAlgetaacq. by BayerDynavaxacq. by SanofiFerroKin Biosciencesacq. by ShireFive Prime Therapeuticsacq. by Amgen
Portfolio news
latest coverage across their companies
Aprea · biospace.com · Sep 10, 2026
CurifyLabs · techfundingnews.com · Jul 6, 2026
Esperion Therapeutics · stocktitan.net · Jun 8, 2026
Pulmonx Corp. · trysignalbase.com · May 12, 2026
Pretzel Therapeutics · finsmes.com · Jul 14, 2025
IPO stake values · per SEC filings · 2
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| Hemab Therapeutics | 4.3% | $18.00 | May 2026 | $34.1M |
| Spruce Biosciences | 8.0% | $15.00 | Oct 2020 | $26.8M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Frequently asked questions
- How many investments has HealthCap made?
- HealthCap has 126 tracked investments, 7 of which have exited, including 5 dated in the last 24 months.
- What stage does HealthCap invest at?
- HealthCap invests at the Seed, Series A, Series B, Series C, Growth stages.
- What sectors does HealthCap focus on?
- HealthCap focuses on Biotech, Digital Health, Healthtech, Longevity, Medical Devices.
- Where is HealthCap located?
- HealthCap is headquartered in Stockholm, SE.
- Does HealthCap lead rounds?
- HealthCap has led 3 of the 10 rounds where its role is on record.
- Who does HealthCap co-invest with?
- HealthCap most often shares deals with Industrifonden, Aisling Capital, Birk Venture, among 97 tracked co-investors.
- What size deals does HealthCap back?
- Across 13 deals with disclosed amounts, HealthCap has joined rounds of $7M – $105M (median $32M).
Media · Podcasts & interviews
featuring the teamHealthcare Direkt v.49: Varför är styrelsen viktig? Gäst: Staffan Lindstrand, Partner Healthcap
Direkt Studios · Staffan Lindstrand
Images
Co-investors · 11
Ysios Capital is a life sciences venture investor that finances innovative biotech companies developing novel therapies for high unmet medical needs, primarily across Europe and the United States.
Abingworth is a life science venture capital firm that backs early-stage biopharma and biotech companies, helping entrepreneurs translate scientific discoveries into new therapeutics.
RA Capital Management is a healthcare and planetary health investment firm that founds, funds, and scales companies using scientific diligence, multi-stage capital, and hands-on operational support.
Vida Ventures is a life sciences venture capital firm focused on transforming biomedical innovations into therapies that improve patients' lives.
Pontifax is a venture capital firm focused on life sciences and healthcare technologies, investing across all development stages from early-stage startups to clinical-stage growth companies.
GV (Google Ventures) is a venture capital firm that has invested in AI and machine learning since its early days, backing more than 100 AI companies across infrastructure, life sciences, and applications.
ARCH Venture Partners is a venture capital firm that invests in and helps build transformational companies, with a strong focus on the life sciences and biotechnology sector.
Cambridge Innovation Capital (CIC) is a UK-based venture capital firm backing entrepreneurs in life sciences and deep tech, leveraging its position in the Cambridge science and technology ecosystem.
Pureos Bioventures is a venture capital firm that invests in private, innovative drug development companies, with a focus on next-generation biological drugs and drug formats to treat severe diseases.
Earlybird Venture Capital is a European venture capital investor that backs early-stage technology founders with capital, strategic support, and access to an international network.
Firms observed investing alongside HealthCap, from public investor directories. Shared companies are the overlap with HealthCap's recorded portfolio.
Similar investors
GV (Google Ventures) is a venture capital firm that has invested in AI and machine learning since its early days, backing more than 100 AI companies across infrastructure, life sciences, and applications.
Khosla Ventures is a venture capital firm that backs bold, early-stage, technology-driven companies across deep tech and other sectors, providing hands-on 'venture assistance' to help founders build category-defining businesses.
Novo Holdings is the holding and investment company that manages the assets of the Novo Nordisk Foundation, serving as controlling shareholder of Novo Nordisk and Novonesis. It invests in life science companies across all stages and manages a diversified portfolio of equities, bonds, real estate, infrastructure and private equity.
Lumira Ventures is a North American life sciences venture capital firm that partners with mission-driven entrepreneurs to build companies developing and commercializing healthcare products for patients.
OrbiMed is a healthcare-focused investment firm providing tailored financing solutions and global resources to build world-class healthcare companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.